-
Immunology Letters Dec 2016Strongyloides stercoralis is a helminth parasite that can infect millions of people worldwide, particularly in tropical, subtropical and temperate regions with poor... (Review)
Review
Strongyloides stercoralis is a helminth parasite that can infect millions of people worldwide, particularly in tropical, subtropical and temperate regions with poor sanitation. Several aspects of epidemiology, biology and host-parasite interactions of S. stercoralis have been studied, and substantial knowledge has been acquired; however, very few studies on immunotherapeutic control strategies to prevent infection and disease in humans have been conducted. Therefore, this article reviews the current progress and targets toward vaccine and passive immunization approaches for Strongyloides spp.
Topics: Animals; Host-Parasite Interactions; Humans; Immunization, Passive; Strongyloides stercoralis; Strongyloidiasis; Vaccines
PubMed: 27769813
DOI: 10.1016/j.imlet.2016.10.005 -
Expert Review of Anti-infective Therapy 2016Congenital cytomegalovirus infection affects 0.7% of live births and is the leading cause of congenital neurological handicaps of infectious origin. However, systematic... (Review)
Review
Congenital cytomegalovirus infection affects 0.7% of live births and is the leading cause of congenital neurological handicaps of infectious origin. However, systematic screening of this infection has not been implemented in pregnancy or at birth in any country. This apparent paradox has been justified by the unavailability of an efficient vaccine and by the scarcity of data available on the treatment of congenital CMV. However, in the last decade interesting new data on the management of this congenital infection has emerged including new results on both neonatal and postnatal treatments. This review provides an update on the potential benefits of antiviral treatment and on passive immunisation both in the neonatal and the antenatal periods. These suggest a benefit to a proactive approach for neonatal and prenatal congenital infections.
Topics: Antiviral Agents; Cytomegalovirus Infections; Female; Humans; Immunization, Passive; Peripartum Period; Postnatal Care; Pregnancy; Pregnancy Complications, Infectious; Prenatal Care
PubMed: 27043943
DOI: 10.1586/14787210.2016.1173540 -
Human Vaccines & Immunotherapeutics Dec 2020Passive immunotherapeutics (PITs), including convalescent plasma, serum, or hyperimmune immunoglobulin, have been of clinical importance during sudden outbreaks since... (Review)
Review
Passive immunotherapeutics (PITs), including convalescent plasma, serum, or hyperimmune immunoglobulin, have been of clinical importance during sudden outbreaks since the early twentieth century for the treatment of viral diseases such as severe acute respiratory syndrome (SARS), middle east respiratory syndrome (MERS) and swine flu (H1N1). With the recent SARS-CoV-2 pandemic, wherein effective antivirals and vaccines are still lacking, an interest in convalescent plasma therapy as a lifesaving option has resurfaced due to its capacity for antigenic neutralization and reducing viremia. This review summarizes convalescent blood products (CBPs) in terms of current technologies and the shortcomings related to the collection, manufacture, pathogen inactivation, and banking of CBPs, with a specific focus on their plausible applications, benefits, and risks in the COVID-19 pandemic.
Topics: COVID-19; Humans; Immunization, Passive; Risk Assessment; COVID-19 Serotherapy
PubMed: 32962524
DOI: 10.1080/21645515.2020.1808410 -
Immunology and Allergy Clinics of North... Aug 2020Immunoglobulin replacement therapy is standard of care in treatment of many primary immunodeficiency diseases. The goal of replacement therapy is to reduce infections in... (Review)
Review
Immunoglobulin replacement therapy is standard of care in treatment of many primary immunodeficiency diseases. The goal of replacement therapy is to reduce infections in individuals with primary immune deficiency and improve their quality of life. Immunoglobulin replacement therapy is most often lifelong, therefore ease of administration is vital for adherence to treatment. Self-infusion via subcutaneous intravenous immunoglobulin (SCIG) allows patient input to design an individualized and optimal treatment plan. Because SCIG regimens are flexible and allow for increased autonomy, patients receiving SCIG report improved quality of life. This article summarizes the dosing, administration, and adverse event management of SCIG infusions.
Topics: Clinical Decision-Making; Disease Management; Disease Susceptibility; Drug Monitoring; Humans; Immunization, Passive; Immunoglobulins; Immunoglobulins, Intravenous; Infusions, Subcutaneous; Injections, Subcutaneous; Primary Immunodeficiency Diseases; Treatment Outcome
PubMed: 32654697
DOI: 10.1016/j.iac.2020.04.002 -
International Journal of Antimicrobial... Mar 2021The COVID-19 pandemic, caused by SARS-CoV-2, has led to a rapid search for therapeutic and preventive measures because of the potentially severe course of infection. The... (Review)
Review
The COVID-19 pandemic, caused by SARS-CoV-2, has led to a rapid search for therapeutic and preventive measures because of the potentially severe course of infection. The antiviral drug, remdesivir, and the anti-inflammatory agent, dexamethasone, have shown beneficial effects. As the current COVID-19 vaccines are not yet fully available to everyone, or they may not be readily and universally accepted, various treatment options are being evaluated and will still be needed under these conditions. One of these treatment options, passive immunization, has shown promise in some studies. Further research is needed to determine the utility of immunotherapy with convalescent plasma or artificially produced monoclonal antibodies for the treatment of symptomatic patients, and potentially for use as post-exposure prophylaxis, at least until more effective drugs are available or safe and effective vaccines are distributed and administered to everyone.
Topics: Antibodies, Monoclonal; Antiviral Agents; COVID-19; Humans; Immunization, Passive; SARS-CoV-2; COVID-19 Serotherapy
PubMed: 33400975
DOI: 10.1016/j.ijantimicag.2020.106275 -
The American Journal of Nursing Apr 2021
Topics: COVID-19; COVID-19 Vaccines; Humans; Immunization, Passive; International Cooperation; COVID-19 Serotherapy
PubMed: 33755615
DOI: 10.1097/01.NAJ.0000742468.73744.7e -
African Health Sciences Dec 2021In the past years, numerous new fatal infections have emerged, including Ebola, Nipah, and Zika viruses, as well as coronaviruses. Recently, infections with severe acute... (Review)
Review
In the past years, numerous new fatal infections have emerged, including Ebola, Nipah, and Zika viruses, as well as coronaviruses. Recently, infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged in China, and were then transmitted all over the world, causing the coronavirus disease-19 (COVID-19) pandemic, which is transmitted at a higher rate than other diseases caused by coronaviruses. At the time of writing this review, COVID-19 is not contained in most countries in spite of quarantine, physical distancing, and enhanced hygiene measures. In this review, I address different methods for passive and active immunization against this virus, which is known to cause fatal respiratory disease, including natural passive immunization by breast milk, natural active immunization by herd immunization, artificial passive immunization by convalescent plasma or monoclonal antibodies, and artificial active immunization by vaccination. I hope this review will help design a prophylactic approach against outbreaks and pandemics of related coronaviruses in the future.
Topics: COVID-19; Disease Outbreaks; Humans; Immunization, Passive; SARS-CoV-2; Vaccination; Zika Virus; Zika Virus Infection; COVID-19 Serotherapy
PubMed: 35283984
DOI: 10.4314/ahs.v21i4.11 -
Blood Transfusion = Trasfusione Del... Mar 2020
Topics: Betacoronavirus; Blood Transfusion; COVID-19; Coronavirus Infections; Disease Outbreaks; Humans; Immunization, Passive; Pandemics; Pneumonia, Viral; SARS-CoV-2; COVID-19 Serotherapy
PubMed: 32267830
DOI: 10.2450/2020.0076-20 -
The Lancet. Haematology Oct 2018
Topics: Hepatitis B Antibodies; Humans; Immunization, Passive
PubMed: 30290900
DOI: 10.1016/S2352-3026(18)30158-3 -
Human Vaccines & Immunotherapeutics 2019
Topics: Hepatitis; Humans; Immunization, Passive; Immunotherapy; Influenza, Human; Meningococcal Infections; Pneumococcal Infections; Vaccines
PubMed: 30794094
DOI: 10.1080/21645515.2019.1571854